TP53 and cancer: Pathogenic missense variants in TP53 often disrupt the function of the wild type protein (dominant negative effect); this leads to loss of p53 function, even before the evolving cancer cell develops loss or amplification of genomic material, and often leads to a more severe Li–Fraumeni phenotype 23, 24, 25, 26, 27, 28.